933785-12-7

Basic information

• Product Name: 4-(1-(4-broMophenyl)ethyl)Morpholine
• Synonyms: 4-(1-(4-broMophenyl)ethyl)Morpholine
• CAS NO: 933785-12-7
• Molecular Formula: C₁₂H₁₆BrNO
• Molecular Weight: 270.16554
• Mol File: 933785-12-7.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(1-(4-broMophenyl)ethyl)Morpholine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(1-(4-broMophenyl)ethyl)Morpholine(933785-12-7)
• EPA Substance Registry System: 4-(1-(4-broMophenyl)ethyl)Morpholine(933785-12-7)

Safety Data

• Hazardous Substances Data: 933785-12-7(Hazardous Substances Data)

Upstream product

• 55779-43-6 4-[1-(4-Bromophenyl)ethenyl]morpholin 
• 766-96-1 4-bromo-1-ethynylbenzene 
• 110-91-8 morpholine 
• 159755-11-0 1-bromo-4-(1-bromoethyl)benzene 
• 1585-07-5 1-bromo-4-ethylbenzene 
• 20488-10-2 1-(1-chloroethyl)-4-bromobenzene 

Downstream Products

• 1206594-12-8 4-(1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyl)morpholine 

Relevant articles and documents

Achieving Aliphatic Amine Addition to Arylalkynes via the Lewis Acid Assisted Triazole-Gold (TA-Au) Catalyst System

Transition metal catalyzed intermolecular hydroamination of the arylalkynes with aliphatic amine is generally problematic due to the good coordination between amine and metal cation. With the combination of 1,2,3-triazole coordinated gold(I) catalyst (TA-Au) and Zn(OTf)2 cocatalyst, this challenging transformation was achieved with good to excellent yields and regioselectivity. Compared to previously reported methods, this approach offered an alternative catalyst system to achieve this fundamental chemical transformation with high efficiency and practical conditions.

NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES

Novel [1,2,4]triazolo[1,5-a]pyridine compounds are disclosed that have a Formula represented by the Formula (I). These compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diseases involving cartilage degradation, bone and/or joint degradation, for example osteoarthritis; and/or conditions involving inflammation or immune responses, such as Crohn's disease, rheumatoid arthritis, psoriasis, allergic airways disease (e.g. asthma, rhinitis), juvenile idiopathic arthritis, colitis, inflammatory bowel diseases, endotoxin-driven disease states (e.g. complications after bypass surgery or chronic endotox in states contributing to e.g. chronic cardiac failure), diseases involving impairment of cartilage turnover (e.g. diseases involving the anabolic stimulation of chondrocytes), congenital cartilage malformations, diseases associated with hypersecretion of IL6 and transplantation rejection (e.g. organ transplant rejection) and proliferative diseases.

NEW PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY AS WELL AS THE USE OF PYRIMIDINE DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR PREVENTION AND/OR TREATMENT OF ALZHEIMER’S DISEASE

The present invention relates to use of compounds of formula (I) as a free base or a pharmaceutically acceptable salt, solvate or solvate of salt thereof, a process for their preparation and new intermediates used therein, as pharmaceutical ingredients fo